-33%

est. 2Y upside i

HealthcareRobotics

Robotic production capacity for the pharma manufacturing industry

Rank

#36

Sector

Biotechnology, Robotics, Healthcare Technology

Est. Liquidity

~4Y

Data Quality

Data: Medium

Multiply Labs presents a strong upside opportunity for a job seeker, driven by its innovative robotic technology addressing a critical bottleneck in the rapidly growing cell therapy manufacturing market.

Last updated: March 10, 2026

Bull (25%)+400%

Multiply Labs achieves significant market penetration and scales multiple strategic partnerships (e.g., AstraZeneca, Thermo Fisher, NVIDIA), driving revenue to $50M-$70M and justifying a $300M valuation (5x current) as a leader in automated cell therapy manufacturing.

Base (45%)+233%

The company continues to grow steadily, securing key customer wins and expanding existing partnerships, reaching $25M-$35M in revenue and a $200M valuation, reflecting solid execution in a competitive but growing market.

Bear (30%)-70%

Multiply Labs faces significant regulatory delays or increased competition, leading to slower adoption and revenue growth of $15M-$20M. A challenging funding environment forces a down round to $18M, severely impacting common stock value due to the $41.3M liquidation preference.

Est. time to liquidity~3.5 years

Preference Stack Risk

severe

Funding Intensity

69%

Investors hold $41.3M in liquidation preferences. In an exit at $60M, common shareholders would see $18.7M distributed; if the exit is at or below $41.3M, common shareholders get nothing.

Dilution Risk

high

As a Series A company in a high capital intensity sector, Multiply Labs will likely require multiple additional funding rounds, leading to further dilution for existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Multiply Labs' equity at this stage.

Robotics Software — 3 roles

Software — 2 roles

Biosciences — 1 role

Engineering Leadership — 1 role

Finance — 1 role

Open Application — 1 role

View all 16 open roles at Multiply Labs →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Multiply Labs's data — designed to show you've done your homework.

  • 1

    “How is Multiply Labs strategically planning to maintain its strong competitive moat against potential in-house automation solutions from large biopharma CDMOs or new entrants from the traditional robotics sector?”

  • 2

    “Given the high capital intensity and regulatory environment of biopharma manufacturing, what are the key operational and financial milestones the company is focused on achieving in the next 18-24 months to ensure a successful Series B or C funding round?”

  • 3

    “Considering the significant $41.3M liquidation preference on a $60M valuation, what is the company's long-term strategy for ensuring common stock holders see meaningful returns, particularly if an exit valuation is closer to the total capital raised?”

Community

Valuation Sentiment

Our model estimates -33% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.